Table 3.

Unadjusted and multivariable-adjusteda logistic regression analyses of the associations between higher ALb and unfavorable breast cancer clinicopathologic characteristics among Black breast cancer survivors in the Women's Circle of Health Follow-Up Study (2014–2018), by AL measure cohort.

AL measure 1c cohort (n = 229)AL measure 2d cohort (n = 409)
UnadjustedMultivariable-adjustedUnadjustedMultivariable-adjusted
OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
Tumor behavior: invasive (stage I, II, and III) vs. noninvasive (stage 0 or DCIS)
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)1.00 (referent)1.00 (referent)
  Higher (4–8)1.09 (0.56–2.14)1.23 (0.62–2.47)1.02 (0.63–1.64)1.20 (0.72–1.99)
P = 0.79P = 0.56P = 0.95P = 0.49
Tumor grade: poorly differentiated vs. well and moderately differentiated
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)1.00 (referent)1.00 (referent)
  Higher (4–8)1.87 (1.06–3.30)2.16 (1.18–3.94)1.15 (0.77–1.71)1.60 (1.02–2.51)
P = 0.03P = 0.01P = 0.51P = 0.04
Tumor size: ≥2 cm vs. <2 cm
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)1.00 (referent)1.00 (referent)
  Higher (4–8)0.90 (0.51–1.60)1.00 (0.55–1.84)1.22 (0.81–1.83)1.58 (1.01–2.46)
P = 0.72P = 0.99P = 0.34P = 0.04
ER status: ER vs. ER+
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)1.00 (referent)1.00 (referent)
  Higher (4–8)1.17 (0.62–2.20)1.12 (0.59–2.16)1.24 (0.78–1.98)1.23 (0.75–2.01)
P = 0.64P = 0.73P = 0.36P = 0.41
  • Note: All stage 0 cases were classified as tumor size <2 cm. Bold values indicate statistical significance.

  • aThe following covariates were included in the multivariable-adjusted regression analyses: (i) age at diagnosis; (ii) birthplace; (iii) marital status; (iv) menopausal status; (v) family history of breast cancer.

  • bThe median AL score among Women's Circle of Health Follow-Up Study participants was 3. Thus, 3 was used as the cutoff point to dichotomize the allostatic load variable.

  • cAL measure 1 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, HDL, triglycerides, total cholesterol and/or LDL, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • dAL measure 2 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, albumin, eGFR, BMI, and use of medication to control hypertension, hypercholesterolemia, or diabetes.